Tin tức & Cập nhật
Xem bài viết Dược
Xem

Refractory Crohn’s disease responds well to risankizumab
In the treatment of patients with luminal Crohn’s disease and multiple prior drug failures, risankizumab induces clinical response in about three out of four patients and steroid-free clinical remission in about half, according to a study.

Oseltamivir as good as peramivir in influenza B but yields better outcomes in influenza A
Oseltamivir appears to have similar efficacy as peramivir in the treatment of young children with severe influenza B, a study has found. However, oseltamivir treatment leads to better recovery and shorter hospitalization in children with severe influenza A.

Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.

Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
Adagrasib appears to have some effect against metastatic, KRAS G12C-mutated colorectal cancer when used in treatment-experienced patients either as oral monotherapy or in combination with cetuximab, according to the results of a phase I-II, open-label study.

Cardiovascular, mortality outcomes in hypertension similar between two thiazide diuretics
The use of chlorthalidone in the treatment of patients with hypertension does not appear to provide better protection against major cardiovascular outcome events or noncancer-related deaths when compared with hydrochlorothiazide, according to a study.

Investigational antisense oligonucleotide for chronic HBV infection shows positive results
Treatment with the antisense oligonucleotide bepirovirsen appears to lead to sustained loss of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA in up to 10 percent of patients with chronic HBV infection, according to the results of the phase IIb study B-Clear.



